New drug has potential to turn COVID-19 virus against itself Scripps Research team showed that a variation of an already FDA-approved therapeutic for neurological disease can block COVID-19 infection in animals.
September 29, 2022
LA JOLLA, CA A new drug designed by scientists at Scripps Research can turn the COVID-19 virus into a harbinger of its own doom.
The drug, NMT5, described in Nature Chemical Biology on September 29, 2022, coats SARS-CoV-2 with chemicals that can temporarily alter the human ACE2 receptor the molecule the virus normally latches onto to infect cells. That means that when the virus is near, its path into human cells via the ACE2 receptor is blocked; in the absence of the virus, however, ACE2 can function as usual.
What's so neat about this drug is that we're actually turning the virus against itself, says senior author Stuart Lipton, MD, PhD, the Step Family Endowed Chair and Scripps Research professor. We're arming it with little molecular warheads that end up preventing it from infecting our cells; it's our revenge on the virus.
Before the COVID-19 pandemic, Lipton and his colleagues had long been studying variations of the drug memantine, which Lipton developed and patented in the 1990s for treating neurological diseases like Alzheimer's. While memantine originated from an anti-influenza drug used in the 1960s, clinicians began investigating it for additional diseases after they noticed a woman with Parkinson's symptoms improved when she took the drug for the flu.
My team had made these antiviral drugs better for the brain, and when COVID-19 emerged, we wondered whether we had also, in the process, made any of them better antivirals, says Lipton.
Lipton and his team tested a library of compounds similar to memantine in overall structure but covered with additional pharmacological warheads. They pinpointed the drug candidate designated NMT5 as having two key properties: It could recognize and attach to a pore on the surface of SARS-CoV-2, and it could chemically modify human ACE2 using a fragment of nitroglycerin as the warhead. The group realized this could turn the virus into a delivery vehicle for its own demise.
In the new paper, Lipton's group characterized and tested NMT5 in isolated cells as well as animals. They showed how NMT5 attaches tightly to SARS-CoV-2 viral particles as the viruses move through the body. Then, they revealed the details of how the drug adds a chemical (similar to nitroglycerin) to certain molecules if it gets close enough. When the virus gets near ACE2 to infect a cell, that translates into NMT5 adding a nitro group to the receptor. When ACE2 is modified in this way, its structure temporarily shifts for about 12 hours so that the SARS-CoV-2 virus can no longer bind to it to cause infection.
What's really beautiful is that this only knocks down availability of ACE2 locally when the virus is coming at it, says Lipton. It doesn't knock down all the function of ACE2 elsewhere in the body, allowing for normal function of this protein.
In cell culture experiments testing how well the Omicron variant of SARS-CoV-2 can attach to human ACE2 receptors, the drug prevented 95% of viral binding. In hamsters with COVID-19, NMT5 decreased virus levels by 100-fold, eliminated blood vessel damage in the animals' lungs, and ameliorated inflammation. The drug also showed effectiveness against nearly a dozen other variants of COVID-19, including alpha, beta, gamma and delta strains.
Most anti-viral drugs work by directly blocking part of a virus which can pressure the virus to evolve resistance to the drug. Since NMT5 is only using the virus as a carrier, the researchers think the drug is likely to be effective against many other variants of SARS-CoV-2.
We expect this compound would continue to be effective even as new variants emerge, because it doesn't rely on attacking parts of the virus that commonly mutate, says Chang-ki Oh, a senior staff scientist and first author of the new paper.
Though they have only studied the compound in animal models, the team is now making a version of the drug to evaluate for human use, while carrying out additional safety and effectiveness trials in animals. This work is being sponsored by the Scripps Center Grant for Antiviral Medicines & Pandemic Preparedness (CAMPP AViDD) from the National Institutes of Health (U19 AI171443).
These exciting findings suggest a new avenue for drug development that requires drug combinations for effective pandemic preparedness, says co-author Arnab Chatterjee, PhD.
In addition to Lipton, Oh and Chatterjee, authors of the new paper are Tomohiro Nakamura, Nathan Beutler, Xu Zhang, Juan Pi a-Crespo, Maria Talantova, Swagata Ghatak, Dorit Trudler, Lauren N. Carnevale, Scott R. McKercher, Malina A. Bakowski, Jolene K. Diedrich, Amanda J. Roberts, Ashley K. Woods, Victor Chi, Anil K. Gupta, Namir Shaabani, Hejun Liu, Ian A. Wilson, Dennis R. Burton, John R. Yates III and Thomas F. Rogers of Scripps Research; Mia A. Rosenfeld, Fiona L. Kearns, Lorenzo Casalino and Rommie E. Amaro of UCSD; and Cyrus Becker of EuMentis Therapeutics, Inc.
This work was supported in part by grants from the National Institutes of Health (RF1 AG057409, R01 AG056259, R01 DA048882, R35 AG071734 and DP1 DA041722, R01 AG061845, R61 NS122098, RF1 NS123298, UM1 AI144462, P41 GM103533, HOPE T32 Training Grant T32AI007384), the California Institute for Regenerative Medicine (DISC2 COVID19-11811), COVID-19 awards from Fast Grants, and the Bill & Melinda Gates Foundation (OPP1107194, INV-004923).
Lipton is an inventor of patents for the use of memantine and related compounds for neurodegenerative and neurodevelopmental disorders. He is also an inventor of composition of matter patents and use patents for aminoadamantane nitrate compounds like NMT
North America Stories
23/07/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
23/07/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
23/07/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
23/07/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
23/07/2026
Witbe brings its AI-native testing and monitoring infrastructure to Amsterdam: demonstrations on real devices, a peer-reviewed technical paper in the conference...
23/07/2026
Quickplay, Caretta Research, Evergent, and Yospace have announced that the renowned IBC Pride Happy Hour will once again bring the vibe and fun back to IBC on F...
23/07/2026
At IBC2026, Interra Systems will present this year's focus: operational AI at scale for QC, monitoring, and captioning workflows. The industry has moved pas...
23/07/2026
Illusionfx is finally coming!
Alex Perea July 23, 2026
0 Comments
The new website is now live to mark the occasion.
Since the last update, feedback h...
23/07/2026
Evergent (5.A86) will showcase its Agentic Revenue Orchestration Platform for streaming services, sports leagues, pay-TV operators at IBC2026 (RAI Amsterdam, 11...
23/07/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
23/07/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
23/07/2026
David Dvir, 2D founder (left), Sundeep Reddy (center), and Jean-Marc Bouchut (right), both of Zeiss...
23/07/2026
Lock in and load up the cloud. GFN Thursday brings fresh updates and new adventu...
22/07/2026
Among other tweaks to coverage, the broadcaster added announce positions in the ...
22/07/2026
The Australian Sports Technologies Network (ASTN) has reported a sharp acceleration in Australia's sportstech sector, with revenue growth rising from 10% in...
22/07/2026
From a retrofitted broadcast bus to packed Match Day Live! events, Bennett detai...
22/07/2026
TMRW Sports has named Brendan Donohue as President, Flag Football, where he will lead the company's professional flag football business in partnership with ...
22/07/2026
Stephen Arnold Music (SAM) designed and produced soundtracks for nine projection...
22/07/2026
Harmonic has announced a $25,000 donation to Global Empowerment Mission (GEM) fo...
22/07/2026
Telemundo has announced it has acquired from UC3 exclusive U.S. Spanish-language...
22/07/2026
The Rest Is Football, hosted by Gary Lineker, Alan Shearer, and Micah Richards, ...
22/07/2026
Sports Studio has announced a partnership with TheSoul Group to distribute Free ...
22/07/2026
Daktronics has concluded its 2026 High School Video Summit, a two-day hybrid event combining virtual sessions with hands-on host school visits across the countr...
22/07/2026
FOR-A America will exhibit at the MMCA Show in Pensacola, Florida (July 21-24), marking the company's first appearance at the house of worship AV event. FOR...
22/07/2026
The New York Yankees have selected Lumen Technologies (NYSE: LUMN) to connect Ya...
22/07/2026
Calrec will exhibit at IBC 2026 (Stand 8.C47) with demonstrations of its IP-native audio ecosystem built around the Argo console range, and will announce two ne...
22/07/2026
Solid State Logic has announced the appointment of Algam EKO as its distributor for SSL large format consoles in Italy, covering the Live, Broadcast, and Studio...
22/07/2026
FloSports has announced the launch of the FloSports Channel, a free ad-supported streaming channel premiering on Prime Video in the U.S. on July 21. The channel...
22/07/2026
Banana Ball TV (BTV), the broadcast operation of the Savannah Bananas, has insta...
22/07/2026
SiriusXM and Audacy have announced an agreement bringing 42 Audacy sports, news, and talk stations from 29 U.S. markets to SiriusXM. Twenty-three Audacy sports ...
22/07/2026
The collaboration produced more than 500 short-form videos across four cities th...
22/07/2026
At 2,600 sq. ft., the new home of digital content houses a main studio, podcast space, and an auxiliary control room
NFL franchises are accelerating their prod...
22/07/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
22/07/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
22/07/2026
Proven managed IP solution helps broadcasters confidently navigate the future of broadcast distribution
LTN announces it has completed successful satellite-to-...
22/07/2026
Today, Chaos announced V-Ray 7, update 4, eliminating the need for asset conversions and tool switching, which slow down media and entertainment pipelines. Arti...
22/07/2026
An AI playground for the Project Indigo camera app
Marc Levoy July 22, 2026
0 Comments
At left is the user interface of our Playground, running on an ...
22/07/2026
Custom Consoles announces the completion of a large technical furniture project for Radio T l vision Suisse (RTS) at the networks recently inaugurated productio...
22/07/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
22/07/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
22/07/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
22/07/2026
Culver City, CA, July 21, 2026 3D streaming infrastructure provider Miris today announced glTF intake, including the binary .glb form, to its spatial streamin...
22/07/2026
Documentary Lo Invisible Captured with Blackmagic PYXIS 6K
Brie Clayton July 21, 2026
0 Comments
Camera's versatile design allowed filmmakers to c...
22/07/2026
AAF Bridge converts AAF and XML Timelines to Ableton Live - and back
Jerome Gardier July 21, 2026
0 Comments
A two-way converter for macOS and Windows...
22/07/2026
From Class to Concert: Explore a Student-Led Production of David Bowies Work Thr...
22/07/2026
NVIDIA founder and CEO Jensen Huang today visited the Naval Postgraduate School in Monterey, California, to commission an NVIDIA DGX GB300 system - bringing one...
22/07/2026
Before a healthcare robot can be useful in the real world, it has to learn how the physical world pushes back. Anatomy varies. Instruments bend, press, slip and...
21/07/2026
With winners Spain having already paraded the World Cup trophy through Madrid in front of millions of fans and the dust now settling on an epic tournament of th...
21/07/2026
In a time of disarray in regional sports broadcasting, the league will provide c...
New drug has potential to turn COVID-19 virus against itself Scripps Research team showed that a variation of an already FDA-approved therapeutic for neurological disease can block COVID-19 infection in animals.
